
Context Euonymus alatus (Thunb.) Siebold has been traditionally used in East Asian medicine for dysentery and inflammatory disorders. However, its effects on intestinal inflammation and barrier injury remain unclear.Objective To evaluate E. alatus extract (EEA) in dextran sulfate sodium (DSS)-induced colitis and examine inflammatory, inflammasome-related, pyroptosis-associated, and epithelial barrier responses.Materials and methods EEA was profiled using ultra-high-performance liquid chromatography–tandem mass spectrometry. Colitis was induced in male C57BL/6 mice (five groups, n = 8/group) using two cycles of 2.0% DSS in drinking water (6 and 5 days of DSS exposure separated by a 7-day DSS-free interval). Cytokine-stimulated Caco-2 epithelial cells and lipopolysaccharide/adenosine triphosphate-stimulated J774A.1 macrophages were also used. Histological and molecular assessments, barrier assays, RNA sequencing, and network pharmacology analyses were performed.Results EEA contained flavonoids and phenolic and reduced weight loss, disease activity, and histological injury; high-dose EEA increased colon length from 6.67 ± 0.18 to 7.58 ± 0.13 cm (p = 0.003 vs. N.C.). EEA decreased MPO- and F4/80-positive infiltration and inflammatory/inflammasome-related transcripts. In Caco-2 cells, EEA improved barrier function and increased ZO-1 and occludin expression. In J774A.1 macrophages, EEA reduced pyroptotic cell death, IL-1β and IL-18 release, ASC oligomerization and specks, cleaved caspase-1, mature IL-1β, and GSDMD-NT. Selected phytochemicals partly reproduced these effects. Transcriptomic and network analyses implicated inflammatory and barrier-related pathways.Discussion and conclusions EEA attenuated DSS-induced experimental colitis and modulated inflammatory, inflammasome-related, epithelial barrier, and pyroptosis-associated responses. Further validation in other experimental models is needed to establish its broader relevance to IBD.
Context Current anti-inflammatory drugs often cause significant adverse effects, underscoring the need for safer alternatives. Natural products with rare and distinctive scaffolds represent a promising source of leads for discovering new anti-inflammatory agents.Objective This study aimed to find anti-inflammatory flavonoid-sesquiterpenoid hybrids from Syzygium simile (Myrtaceae), and to clarify the structural-activity relationship underlying their inhibition of biomarkers in activated human neutrophils.Materials and methods A range of chromatographic techniques was sequentially applied to isolate pure compounds, the structures of which were elucidated by spectroscopic and spectrometric analyses. Anti-inflammatory activities were evaluated in fMLP/CB-induced human neutrophils by measuring inhibitory effects on superoxide anion generation and elastase release.Results Twenty-two flavonoid-sesquiterpenoid hybrids, including thirteen previously undescribed structures, were isolated from S. simile leaves, comprising five flavonoid scaffolds (types I–V) and five sesquiterpenoid moieties (germacrene-, cubebene-, oplopene-, cadinene-, and copaene-types) generated via distinctive electron transfer-mediated biosynthesis. Most compounds potently inhibited superoxide anion generation and elastase release, with IC50 values up to 32-fold lower than that of the positive control, without exhibiting cytotoxicity.Discussion and Conclusion Structure-activity relationship analysis revealed that the combination of a type I flavonoid and a germacrene-type sesquiterpenoid skeleton, integrated through an rA-type ring fusion, represents the optimal pharmacophore. The lead compound, simisyzygin C (3), achieved nanomolar potency with IC50 values of 0.04 μM (superoxide anion) and 0.16 μM (elastase release). These findings identify flavonoid-sesquiterpenoid hybrids as a structurally distinctive class of anti-inflammatory natural products, providing a structural basis for lead optimization.
Context High-quality evidence on Lianhua Qingwen (LHQW) for treating influenza in children remains limited.Objective To evaluate the efficacy and safety of LHQW in children aged 3–14 years with influenza, compared with oseltamivir.Materials and methods In this multicenter, randomized, double-blind, positive parallel-controlled trial, participants were randomly assigned (1:1) to receive either LHQW + oseltamivir placebo or oseltamivir + LHQW placebo. The primary outcome was clinical recovery time. Secondary outcomes included time to defervescence, symptom scores on the Canadian Acute Respiratory Illness and Flu Scale, the incidence of complications and severe/critical influenza, and the improvement rates for individual influenza symptoms. Safety outcomes were assessed based on adverse events.Results A total of 520 participants were randomized (260 per group). Baseline characteristics were comparable. Median clinical recovery time was 5 days in both groups, with similar clinical recovery rates (71.5% vs. 71.2%; HR: 1.04, 95% CI: 0.84–1.29; one-sided p < 0.025). Median time to defervescence was shorter with LHQW (24 h vs. 30 h, p < 0.05). LHQW showed higher improvement rates for cough (56.9% vs. 45.5%) and sore throat (90.9% vs. 74.2%) (both p < 0.05). No severe or critical influenza occurred in the LHQW group. Adverse events incidence was similar between groups (p > 0.05).Discussion LHQW may offer a safe and effective alternative to oseltamivir for pediatric influenza, with particular benefits for defervescence, cough, and sore throat.Conclusions LHQW was non-inferior to oseltamivir in clinical recovery time and resulted in faster defervescence and greater improvement in cough and sore throat, with comparable safety.Clinical trial registration number ChiCTR1900028390 (Chinese Clinical Trial Registry, Dec. 20, 2019)
Context Fridericia chica (Bonpl.) L.G. Lohmann is a medicinal plant rich in bioactive 3-deoxyanthocyanidins with reported wound-healing and gastroprotective properties. A 70% tocotrienol-enriched fraction (TRF) from Bixa orellana L. exhibits antioxidant and anti-inflammatory activities that may complement those of F. chica in gastric mucosal protection.Objective This study aimed to evaluate the gastroprotective and gastric tissue-repair effects of the F. chica-TRF combination.Materials and methods Dry F. chica standardized crude extract alone or combined with TRF at different proportions was tested in vitro in HaCaT keratinocytes and 3T3 fibroblasts to assess cell viability and select a suitable combination ratio for subsequent in vivo investigation. The selected ratio was then investigated in acute and chronic gastric ulcer models in female Wistar rats.Results Among the proportions tested in vitro, the 90:10 (F. chica:TRF) ratio showed the most favorable cell-viability profile and was selected for in vivo evaluation. The combination reduced gastric lesions and significantly increased gastric mucus production. In the chronic ulcer model, treatment was associated with reduced TNF-alpha and IL-1 beta levels and increased IL-10 levels. Histopathological and second-harmonic generation analyses qualitatively indicated mucosal preservation, tissue organization, and collagen deposition.Conclusions The F. chica-TRF combination exhibited gastroprotective effects associated with increased mucus production and modulation of inflammatory mediators. Qualitative morphological findings further indicated preservation of gastric tissue architecture and collagen organization, supporting the potential of this combination as a natural product-based approach to gastric mucosal protection.
Context Atopic dermatitis is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction and dysregulated type 2 helper T cell (Th2)-mediated immune responses. Erigeron annuus (L.) Desf. is traditionally used for inflammatory conditions, but its effects on atopic dermatitis remain unclear.Objective This study evaluated the protective effects of E. annuus aqueous extract (EA) and associated mechanisms.Materials and methods Atopic dermatitis-like lesions were induced in 5-week-old female BALB/c mice by repeated epicutaneous ovalbumin (OVA) sensitization, and EA was orally administered for six weeks. Epidermal barrier function, histopathology, immunoglobulins, cytokines, and mitogen-activated protein kinase (MAPK) signaling were evaluated. Pyromeconic acid (PA), a representative constituent of EA, was examined in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.Results EA attenuated dermatitis-like lesions and reduced dermatitis scores in OVA-sensitized mice. EA decreased transepidermal water loss, increased skin hydration, restored filaggrin expression, and reduced epidermal and dermal thickening, mast cell infiltration, CD4+/CD8+ T-cell accumulation, splenomegaly, serum total and OVA-specific IgE, and skin interleukin-4 and interleukin-13 levels. EA also reduced extracellular signal-regulated kinase and p38 phosphorylation and interleukin-1 beta expression in dorsal skin. PA suppressed MAPK activation and inflammatory mediator expression in LPS-stimulated macrophages.Discussion and conclusion EA attenuated OVA-induced atopic dermatitis-like inflammation in association with improved epidermal barrier function, reduced Th2-associated immune responses, and attenuated MAPK signaling. PA showed anti-inflammatory activity in vitro, although its contribution to the in vivo effects of EA remains to be established. EA warrants further investigation as a plant-derived candidate for complementary intervention in atopic dermatitis.